Product News

Why RT-qPCR leaves gaps in gene expression data

Plasmidsaurus RNA-Seq now screens for mycoplasma contamination, confirms cell-line identity, and enables virtual qPCR panels — all from a single $50 sequencing run.
Written bySharon Dong
Brought to you byPlasmidsaurus
| 4 min read
A researcher reviews an RNA-Seq gene expression heatmap on a laboratory monitor, illustrating transcriptome-wide analysis as an alternative to RT-qPCR.

RNA-Seq transcriptome-wide gene expression analysis delivers results in days, replacing targeted RT-qPCR panels for routine research.

​Google Flow (2026)

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) has been a workhorse of gene expression analysis for decades, but it only measures transcripts the researcher thought to include before the experiment began. A result implicating something outside the panel means designing a new assay from scratch. RNA sequencing captures the full transcriptome in a single run, yet cost, turnaround time, and bioinformatics complexity kept it outside routine laboratory use until recently.

Plasmidsaurus, a sequencing-as-a-service company, launched its RNA-Seq service in October 2025 at a price point and turnaround time intended to lower the barrier to transcriptome-wide profiling. One year on, the company reports that more than 9,000 researchers at over 1,000 institutions have adopted the service, with hundreds of thousands of samples processed. The first anniversary also brought three new platform additions: built-in cell-line identification, mycoplasma contamination screening, and virtual qPCR analysis tools that allow researchers to query transcriptome-wide data using the gene-set logic of a targeted RT-qPCR panel.

How does 3′ RNA-Seq differ from full-length sequencing?

Plasmidsaurus RNA-Seq uses three-prime end counting, a method that sequences the terminal portion of each polyadenylated transcript rather than reads distributed across the full RNA length. Because most differential gene expression analysis requires knowing how many copies of a given transcript are present, three-prime counting produces the same usable expression matrix as full-coverage RNA-Seq at a fraction of the library preparation cost. Unique molecular identifiers (UMIs) added during complementary DNA (cDNA) synthesis allow the pipeline to distinguish true transcript copies from PCR duplicates introduced during amplification.

Results arrive through an interactive analysis platform within three days for US and European submissions, or approximately one week for international shipments. The service covers RNA extraction from cells preserved in Zymo DNA/RNA Shield, library preparation, Illumina sequencing, and analysis output, with no minimum order size.

Four capabilities extract additional quality control data from the same sequencing run, with no extra samples or steps required:

  • Virtual qPCR analysis: Researchers define custom gene sets matching any commercial RT-qPCR array panel and compare expression across samples using existing transcript-level data. These virtual panels can be expanded retroactively to include additional genes, with no need to rerun the assay.
  • Cell-line identification: The service uses RNA-Seq reads to verify species and confirm cell-line identity against a reference database, flagging potential cross-contamination before results are interpreted. No additional sample or sequencing step is required.
  • Mycoplasma screening: Enabled by default for academic customers, the service detects mycoplasma sequences in the same RNA-Seq data already generated for expression analysis. Studies screening mammalian cell-line archives have found contamination in 15 to 35 percent of tested cultures, with infection shown to dysregulate hundreds of host genes and invalidate expression data from affected samples.
  • Automated batch correction: For studies that span multiple plates or submission timepoints, the platform applies automated batch correction to remove technical variation that would otherwise mask biological differences across large longitudinal datasets.

RNA-Seq adoption: 1,000-plus institutions in year one

Plasmidsaurus RNA-Seq has been cited in over 100 peer-reviewed publications including papers in Nature, Science, and Nature Biotechnology, spanning academic medical centers, bioengineering labs, and biopharmaceutical companies in its first year. Among the citing studies is work from Heather Karner and colleagues at the University of California, San Francisco (UCSF), who profiled mRNA stability across six breast cancer cell-line models in a Science Advances paper published in March 2026. "Plasmidsaurus RNA-Seq helped me publish faster," said Karner, whose team went from sample submission to publication in approximately 2.5 months.

Mark Budde, CEO and co-founder of Plasmidsaurus, said the service was designed to remove the choices that have historically slowed gene expression analysis. "For too long, scientists have had to choose between speed and scale, spending countless hours designing primers and setting up plates just to measure a handful of genes," Budde said. "Plasmidsaurus RNA-Seq is a radically different approach to gene expression, but one that builds on the workflows researchers already know."

Plasmidsaurus RNA-Seq reached researchers beyond US-based institutions through two infrastructure expansions. Following a partnership with Genovis announced in April 2026, researchers can ship purified RNA preserved in SEQguard Dino Preserve at ambient temperature, removing dry-ice requirements for international samples. Plasmidsaurus also expanded infrastructure with a European sequencing hub in Cologne, Germany, and now operates more than 1,300 global dropboxes.

Why hasn't RNA-Seq replaced RT-qPCR for routine use?

Three factors have blocked RNA-Seq from replacing RT-qPCR in routine laboratory use: cost, turnaround time, and bioinformatics complexity. Together they kept transcriptome-wide profiling a one-time project endpoint rather than an iterative tool researchers could reach for repeatedly.

Molly Gasperini, Associate Director of Genome Engineering at the Allen Institute and an early-access user of Plasmidsaurus RNA-Seq, told GenomeWeb the service gives researchers "the expression levels of all transcripts" for comparable time and cost to a small RT-qPCR panel. Anoja Perera, Director of the Sequencing and Discovery Genomics Core at the Stowers Institute for Medical Research, said the service "cannot be beat by core facilities, price- or processing time-wise."

Three-prime counting captures transcript abundance across the whole transcriptome but does not resolve alternative splicing or isoform differences with the same fidelity as full-coverage sequencing. For differential gene expression, that is an accepted tradeoff; applications requiring isoform resolution, such as splice variant characterization, fusion transcript detection, or profiling of non-polyadenylated RNAs, still need full-length methods.

Four approaches to gene expression profiling differ on cost, turnaround, coverage, and analytical burden:

Approach

Per-sample cost (academic)

Typical turnaround

Transcript coverage

Bioinformatics required

RT-qPCR (targeted panel)

~$2–$10 (reagents only)

Same day–2 days

10–500 target genes

None beyond instrument software

Fragmentation-based RNA-Seq (core facility)

$150–$400+

2–4 weeks

Full transcriptome, isoform-resolved

Alignment, normalization, differentially expressed gene (DEG) tools

Three-prime RNA-Seq (Plasmidsaurus)

$50

3 days (US/EU)

Full transcriptome, gene-level counts

Included in service

Multiplexed in-house library prep

Very low per-sample cost at scale; see published benchmarks

Hours (library prep) + sequencing

Full transcriptome, gene-level counts

Requires internal bioinformatics

RNA-Seq enters the routine lab at $50 per sample

One year after launch, Plasmidsaurus RNA-Seq has established a $50-per-sample, three-day turnaround service for transcriptome-wide gene expression analysis that is now used by more than 9,000 researchers across 1,000-plus institutions. The addition of virtual qPCR, cell-line identification, mycoplasma screening, and automated batch correction in the platform's second year extends the number of quality control questions a single sequencing run can address. With sensitivity for low-abundance transcripts and pricing that holds at scale, three-prime counting is well positioned to become the default starting point for routine gene expression work.

This article is based on a press release issued by Plasmidsaurus and was produced under Drug Discovery News' AI Editorial Guidelines.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • black and white picture of sharon dong in button up blouse
    Sharon Dong, BSc (Hons), MSc joined LabX Media Group (LMG) in 2026 as a Product News & Intelligence Editor. She has a strong background in cellular biology, microbiology, immunology, and molecular genetics. She is an experienced science education and outreach facilitator. Sharon is passionate about communicating science in ways that are clear, engaging, and accessible to a broad audience. In her free time, she enjoys solving jigsaw puzzles and cooking. Sharon can be reached at sdong@labx.com.
    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.